Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
ZK 824859 is an inhibitor of urokinase-type plasminogen activator (uPA; IC50s = 79 and 410 nM for the human and mouse proteins, respectively).1 It is selective for human uPA over human tissue-type plasminogen activator (tPA) and plasmin (IC50s = 1,580 and 1,330 nM, respectively) but not selective for mouse uPA over mouse tPA and plasmin (IC50s = 910 and 1,600 nM, respectively). ZK 824859 (25 or 50 mg/kg per day) reduces the incidence of limb weakness and paralysis in mice in a model of experimental autoimmune encephalomyelitis (EAE).
WARNING This product is not for human or veterinary use.
1. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg. Med. Chem. Lett. 28(20), 3372-3375 (2018).